Mometasone furoate monohydrate nasal spray for the treatment of nasal congestion in allergic rhinitis

References

• Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma: ARIA workshop report. J. Allergy Clin. Immunol.108(5 Suppl.), S147–S334 (2001).
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S, Skoner DP et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol.81(5 Pt 2), 478–518 (1998).
   PubMed Web of Science ®Google Scholar
• Rossoff LJ, Stempel DA, Alam R. The health and economic impact of rhinitis. Am. J. Manag. Care3(Suppl.), S8–S18 (1997).
   PubMedGoogle Scholar
• Santos R, Cifaldi M, Gregory C, Seitz P. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am. J. Manag. Care5(Suppl.), S225–S234 (1999).
   PubMedGoogle Scholar
• The UCB Institute of Allergy. European Allergy White Paper. Chapter 5: Socio-economic costs of allergic diseases. (1997).
   Google Scholar
• Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann. Allergy Asthma Immunol.82(3), 296–305 (1999).
   PubMed Web of Science ®Google Scholar
• Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, Leutner D, O’Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann. Allergy71(2), 121–126 (1993).
   PubMedGoogle Scholar
• Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat. Respir. Med.4(6), 439–446 (2005).
   PubMedGoogle Scholar
• Stull DE, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Curr. Med. Res. Opin.23(4), 811–819 (2007).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Bachert C et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy58(3), 192–197 (2003).
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenberge P, Khaled NA et al. Pharmacologic and anti-IgE treatment of allergic rhinitis. ARIA update (in collaboration with GA2LEN). Allergy61(9), 1086–1096 (2006).
   PubMed Web of Science ®Google Scholar
• International Rhinitis Management Working Group. International consensus report on diagnosis and management of rhinitis. Allergy49(19 Suppl.), 1–34 (1994).
   Google Scholar
• Dykewicz MS, Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann. Allergy Asthma Immunol.81(5 Pt 2), 463–468 (1998).
   PubMed Web of Science ®Google Scholar
• van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. Allergy55(2), 116–134 (2000).
   PubMed Web of Science ®Google Scholar
• Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim. Care Resp. J.15(1), 58–70 (2006).
   PubMedGoogle Scholar
• Plaut M, Valentine MD. Allergic rhinitis. N. Engl. J. Med.353(18), 1934–1944 (2005).
   PubMed Web of Science ®Google Scholar
• Horak F. Seasonal allergic rhinitis: newer treatment approaches. Drugs45(4), 518–527 (1993).
   PubMedGoogle Scholar
• Ferguson BJ. Allergic rhinitis: options for pharmacotherapy and immunotherapy. Postgrad. Med.101(5), 117–131 (1997).
   PubMed Web of Science ®Google Scholar
• Busse WW. Role of antihistamines in allergic disease. Ann. Allergy72(4), 371–375 (1994).
   PubMedGoogle Scholar
• Fireman P. Allergic rhinitis. In: Atlas of Allergies (2nd Edition). Fireman P, Slavin RG (Eds.), Mosby-Wolfe, Times-Mirror, London, UK, 9.1–9.18 (1996).
   Google Scholar
• Suonpää J. Treatment of allergic rhinitis. Ann. Med.28(1), 17–22 (1996).
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER, van Oosterwijck AWAA et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J. Allergy Clin. Immunol.111(3), 623–627 (2003).
   PubMed Web of Science ®Google Scholar
• Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy56(11), 1077–1080 (2001).
   PubMed Web of Science ®Google Scholar
• Kim K, Sussman G, Hébert J, Lumry W, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol.96(3), 460–465 (2006).
   PubMed Web of Science ®Google Scholar
• Black MJ, Remsen KA. Rhinitis medicamentosa. Can. Med. Assoc. J.122(8), 881–884 (1980).
   PubMed Web of Science ®Google Scholar
• Bachert C. Persistent rhinitis – allergic or nonallergic? Allergy59(Suppl. 76), 11–15 (2004).
   PubMed Web of Science ®Google Scholar
• American Academy of Allergy, Asthma and Immunology. The allergy report. Vol. 2. Diseases of the Atopic Diathesis. WI, USA (2000).
   Google Scholar
• Bronsky E, Boggs P, Findlay S et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal rhinitis. J. Allergy Clin. Immunol.96(2), 139–147 (1995).
   PubMed Web of Science ®Google Scholar
• Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology34(2), 91–96 (1996).
   PubMedGoogle Scholar
• Gastpar H, Nolte D, Aurich R et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy49(3), 152–158 (1994).
   PubMed Web of Science ®Google Scholar
• Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH. Antihistamines: topical versus oral administration. Clin. Exp. Allergy26(Suppl. 3), 11–17 (1996).
   PubMed Web of Science ®Google Scholar
• Drouin MA, Yang WH, Horak F. Faster onset of action with topical levocabastine than with oral cetirizine. Mediators Inflamm.4(Suppl.), S5–S10 (1995).
   PubMedGoogle Scholar
• MedPointe Healthcare Inc.: Astelin® (azelastine hydrochloride) product information.
   Google Scholar
• Novartis Ophthalmics: Livostin® (levocabastine hydrochloride ophthalmic suspension) product information.
   Google Scholar
• Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy52(Suppl. 36), 29–32 (1997).
   PubMedGoogle Scholar
• Erin EM, Zacharasiewicz AS, Nicholson GC et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin. Exp. Allergy35(12), 1608–1614 (2005).
   PubMed Web of Science ®Google Scholar
• Rak S, Jacobson MR, Sudderick RM et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin. Exp. Allergy24(10), 930–939 (1994).
   PubMed Web of Science ®Google Scholar
• Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol. Immunotoxicol.13(3), 251–261 (1991).
   PubMed Web of Science ®Google Scholar
• Umland SP, Nahrebne DK, Razac BS, Billah MM, Egan RW. Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells. J. Allergy Clin. Immunol.97, 288 (1996) (Abstract 423).
   Google Scholar
• Umland SP, Nahrebne DK, Razac S et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-g production by cultured primary CD4+ T cells. J. Allergy Clin. Immunol.100(4), 511–519 (1997).
   PubMed Web of Science ®Google Scholar
• Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J. Allergy Clin. Immunol.108(1 Suppl.), S59–S64 (2001).
   PubMed Web of Science ®Google Scholar
• Fowler PD, Gazis AG, Page SR, Jones NS. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo–pituitary–adrenal axis and bone turnover in patients with nasal polyposis. Clin. Otolaryngol. Allied Sci.27(6), 489–493 (2002).
   PubMedGoogle Scholar
• Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on hypothalamic–pituitary–adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis (PAR). J. Allergy Clin. Immunol.119, S305 (2007) (Abstract 1191).
   Google Scholar
• Tripathy I, Sterling R, Clements D, Wu W, Faris M, Philpot E. Lack of effect on hypothalamic–pituitary–adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in children with perennial allergic rhinitis (PAR). J. Allergy Clin. Immunol.119, S232 (2007) (Abstract 909).
   Web of Science ®Google Scholar
• Kim KT, Rabinovitch N, Uryniak T, Simpson B, O’Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic–pituitary–adrenal axis function in children with allergic rhinitis. Ann. Allergy Asthma Immunol.93(1), 61–67 (2004).
   PubMed Web of Science ®Google Scholar
• Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf.30(4), 317–326 (2007).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor ML, Pellitteri ME et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin. Exp. Allergy34(2), 259–267 (2004).
   PubMed Web of Science ®Google Scholar
• Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol.109(6), 949–955 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med.116(5), 338–344 (2004).
   PubMed Web of Science ®Google Scholar
• Ädelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol.106(2), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol.91(2), 160–167 (2003).
   PubMed Web of Science ®Google Scholar
• Genentech, Inc.: Xolair® (omalizumab) product information.
   Google Scholar
• Davydov L. Omalizumab (Xolair) for treatment of asthma. Am. Fam. Physician71(2), 341–342 (2005).
   PubMedGoogle Scholar
• Schering Corporation: Nasonex® (mometasone furoate monohydrate) product information.
   Google Scholar
• Onrust SV, Lamb HM. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs56(4), 725–745 (1998).
   PubMed Web of Science ®Google Scholar
• Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin. Pharmacother.4(9), 1579–1591 (2003).
   PubMed Web of Science ®Google Scholar
• Mygind N, Nielsen LP, Hoffmann HJ et al. Mode of action of intranasal corticosteroids. J. Allergy Clin. Immunol.108(1 Suppl.), S16–S25 (2001).
   PubMedGoogle Scholar
• Smith CL, Kreutner W. In vitro glucocorticoids receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung48(9), 956–960 (1998).
   PubMed Web of Science ®Google Scholar
• Linsley PS, Ledbetter JA. The role of CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol.11, 191–212 (1993).
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol. Today13(12), 501–506 (1992).
   PubMedGoogle Scholar
• Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol.7, 145–173 (1989).
   PubMed Web of Science ®Google Scholar
• Crocker IC, Church MK, Newton S, Townley RG. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann. Allergy Asthma Immunol.80(6), 509–516 (1998).
   PubMed Web of Science ®Google Scholar
• Crocker IC, Zhou CY, Bewtra AK, Kreutner W, Townley RG. Glucocorticoids inhibit leukotriene production. Ann. Allergy Asthma Immunol.78(5), 497–505 (1997).
   PubMed Web of Science ®Google Scholar
• Frieri M, Therattil J, Chavarria V et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol.81(5 Pt 1), 431–437 (1998).
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J. Allergy Clin. Immunol.102(1), 39–49 (1998).
   PubMed Web of Science ®Google Scholar
• Lee DKC, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br. J. Clin. Pharmacol.55(3), 310–313 (2003).
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol.60(4), 265–268 (2004).
   PubMed Web of Science ®Google Scholar
• Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol.40(11), 1227–1236 (2000).
   PubMed Web of Science ®Google Scholar
• Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Ther.19(6), 1330–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Bronsky EA, Aaronson DW, Berkowitz RB et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann. Allergy Asthma Immunol.79(1), 51–56 (1997).
   PubMed Web of Science ®Google Scholar
• Berkowitz RB, Roberson S, Zora J et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc.20(3), 167–172 (1999).
   PubMed Web of Science ®Google Scholar
• Berkowitz RB, Bernstein DI, LaForce C et al. Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis. Allergy54(1), 64–69 (1999).
   PubMed Web of Science ®Google Scholar
• Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy51(8), 569–576 (1996).
   PubMed Web of Science ®Google Scholar
• Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann. Allergy Asthma Immunol.90(4), 416–421 (2003).
   PubMed Web of Science ®Google Scholar
• Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Pharmacother.39(12), 1984–1989 (2005).
   PubMedGoogle Scholar
• Meltzer EO, Berger WE, Berkowitz RB et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol.104(1), 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Graft D, Aaronson D, Chervinsky P et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J. Allergy Clin. Immunol.98(4), 724–731 (1996).
   PubMed Web of Science ®Google Scholar
• Pitsios C, Papadopoulos D, Kompoti E et al. Efficacy and safety of mometasone furoate vs. nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol.96(5), 673–678 (2006).
   PubMed Web of Science ®Google Scholar
• Drouin M, Yang WH, Bertrand B et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann. Allergy Asthma Immunol.77(2), 153–160 (1996).
   PubMed Web of Science ®Google Scholar
• Mandl M, Nolop K, Lutsky BN, and Participants in the 194–079 Study Group. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann. Allergy Asthma Immunol.79(4), 370–378 (1997).
   PubMed Web of Science ®Google Scholar
• Bende M, Carrillo T, Vóna I, Castel-Branco MdG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann. Allergy Asthma Immunol.88(6), 617–623 (2002).
   PubMed Web of Science ®Google Scholar
• Tsang RKY, Tong MCF, Woo JKS, Van Hasselt CA. A prospective study on the efficacy of mometasone furoate monohydrate aqueous nasal spray on Chinese patients with allergic rhinitis. Otolaryngol. Head Neck Surg.128(4), 497–502 (2003).
   PubMedGoogle Scholar
• Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J. Allergy Clin. Immunol.108(1 Suppl.), S54–S58 (2001).
   PubMed Web of Science ®Google Scholar
• Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis: effective in relieving ocular symptoms. Allergy Clin. Immunol. Int.19(2), 50–53 (2007).
   Web of Science ®Google Scholar
• Bielory L, Danzig MR, Gates D. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann. Allergy Asthma Immunol. In press (2008).
   Google Scholar
• Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel F-B. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J. Allergy Clin. Immunol.82(5 Pt 1), 869–877 (1988).
   PubMedGoogle Scholar
• Data on file, Schering-Plough Corporation.
   Google Scholar
• O’Brien F, Minshall E, Nolop K et al. Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis. J. Allergy Clin. Immunol.99(Pt 1), S498 (1997) (Abstract 2016).
   Google Scholar
• Minshall E, Ghaffar O, Cameron L et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg.118(5), 648–654 (1998).
   PubMed Web of Science ®Google Scholar
• Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin. Ther.19(1), 27–38 (1997).
   PubMed Web of Science ®Google Scholar
• Brannan MD, Seiberling M, Cutler DL, Cuss FM, Affrime MB. Lack of systemic activity with intranasal mometasone furoate. J. Allergy Clin. Immunol.97(Pt 3), 198 (1996) (Abstract 62).
   Web of Science ®Google Scholar
• Brannan MD, Herron JM, Reidenberg P, Affrime MB. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate. Ann. Allergy Asthma Immunol.78, 154 (1997) (Abstract P207).
   Google Scholar
• Schenkel EJ Skoner DP, Bronsky EA et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics105(2), e22 (2000).
   PubMedGoogle Scholar
• Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr. Asthma Allergy Immunol.19(3), 146–153 (2006).
   Google Scholar
• Agertoft L, Pedersen P. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J. Allergy Clin. Immunol.104(5), 948–952 (1999).
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat. Respir. Med.4(4), 289–296 (2005).
   PubMedGoogle Scholar